J. Goldman & Co LP Purchases New Shares in Geron Corporation $GERN

J. Goldman & Co LP acquired a new stake in shares of Geron Corporation (NASDAQ:GERN) in the 2nd quarter, Holdings Channel reports. The firm acquired 712,124 shares of the biopharmaceutical company’s stock, valued at approximately $912,000.

A number of other institutional investors and hedge funds have also made changes to their positions in the business. Hsbc Holdings PLC bought a new position in shares of Geron in the 2nd quarter valued at about $25,000. Vistica Wealth Advisors LLC bought a new position in shares of Geron during the 4th quarter valued at approximately $33,000. Caitong International Asset Management Co. Ltd raised its stake in shares of Geron by 3,307.6% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 25,148 shares of the biopharmaceutical company’s stock valued at $33,000 after acquiring an additional 24,410 shares during the period. Amundi purchased a new stake in Geron in the 4th quarter worth about $38,000. Finally, OneDigital Investment Advisors LLC bought a new stake in shares of Geron during the second quarter worth $38,000. 73.71% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings raised shares of Geron from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Tuesday, August 11th. Two research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $4.00.

Geron Price Performance

Shares of GERN stock opened at $1.53 on Thursday. The company has a market cap of $982.98 million, a P/E ratio of -13.91 and a beta of 0.61. The company has a debt-to-equity ratio of 0.55, a current ratio of 6.91 and a quick ratio of 5.16. The stock’s 50-day moving average is $1.44 and its 200 day moving average is $1.48. Geron Corporation has a 1-year low of $1.04 and a 1-year high of $2.01.

Geron (NASDAQ:GERN) last released its quarterly earnings results on Wednesday, August 5th. The biopharmaceutical company reported ($0.02) EPS for the quarter, missing the consensus estimate of ($0.01) by ($0.01). The firm had revenue of $57.48 million for the quarter, compared to analysts’ expectations of $55.30 million. Geron had a negative net margin of 34.17% and a negative return on equity of 24.48%. Research analysts predict that Geron Corporation will post -0.04 earnings per share for the current fiscal year.

Geron Profile

Geron Corporation (NASDAQ: GERN) is a clinical-stage biotechnology company dedicated to developing and commercializing novel treatments that target telomerase, an enzyme critical to cancer cell immortality. The company’s research is focused on hematologic malignancies and solid tumors, with a pipeline designed to address diseases that have historically had limited therapeutic options.

The lead product candidate, imetelstat, is a first-in-class telomerase inhibitor currently in Phase II and Phase III clinical trials for myelofibrosis and myelodysplastic syndromes.